Developing a kinase inhibitor drug to treat spinal cord injury
开发治疗脊髓损伤的激酶抑制剂药物
基本信息
- 批准号:10338372
- 负责人:
- 金额:$ 65.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-04 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAnimal ModelAnimal TestingAxonBiological AssayBladderBrainBreathingCellsCenters for Disease Control and Prevention (U.S.)ChemicalsChemistryChronicClinicalClinical TrialsComplexDevelopmentDrug KineticsDrug TargetingEconomic BurdenEffectivenessFailureFamilyGenerationsGoalsGrowthHealth InsuranceHealthcareHealthcare SystemsHeartIn VitroIndividualInjuryIntellectual PropertyInternationalIntestinesInvestigationLeadLegal patentLifeMachine LearningMetabolismModelingMotivationMusNatural regenerationNeuraxisNeuronsParalysedPatientsPersonsPharmaceutical PreparationsPhasePhase I Clinical TrialsPhenotypePhosphotransferasesPropertyProtocols documentationRattusRegenerative capacityReproducibilityResearchRiskSeriesSexual DysfunctionSourceSpinal CordSpinal cord injuryStructure-Activity RelationshipSynthesis ChemistryTestingTherapeuticThinkingToxic effectToxicologyUnited States National Institutes of HealthWorkabsorptionanalogaxon growthaxon injuryaxon regenerationbasecentral nervous system injuryclinical candidatecostdrug candidatedrug developmentimprovedin vivoin vivo evaluationinhibitor therapyinjuredkinase inhibitorlead candidatelead optimizationneuron lossnovelnovel therapeutic interventionpainful neuropathypreclinical developmentpsychologicscreeningsmall moleculetherapeutic candidatetranslational potential
项目摘要
ABSTRACT
Spinal cord injury (SCI) is a devastating condition with life-long consequences that include paralysis. Central
nervous system (CNS) axons typically fail to regenerate, leading to irreversible losses of neuronal connectivity
and associated functions after injury. SCI is now estimated to cost the nation’s healthcare system around $40.5
billion annually (CDC). People living with paralysis are often unable to afford health insurance that adequately
covers the associated complex secondary or chronic conditions, which places tremendous economic burden and
psychological suffering on them and their families. Developing a drug to treat SCI will address major healthcare
and societal needs.
Encouraging axon regeneration in the CNS is challenged by at least two separate mechanisms that suppress
axonal growth: 1) a lack of intrinsic regenerative capacity in adult CNS neurons, and 2) the extrinsic inhibitory
microenvironment confronting damaged axons. Despite decades of research and billions of NIH dollars spent,
there are still no approved drugs for promoting axon regeneration. Moreover, the effectiveness of drugs in
development is likely limited by the fact that each targets only one of the two growth-suppressive mechanisms.
We have discovered the first therapeutic candidate, in the form of a small molecule, which can simultaneously
address both sources of regeneration failure. We accomplished this using a combination of phenotypic
screening, target-based profiling, and machine learning to identify kinase targets within each of the two
mechanisms, extrinsic and intrinsic. We then identified a single small molecule (RO48) that manifests a
polypharmacology profile correlated with unusually robust promotion of axon growth. Remarkably, RO48 showed
high and reproducible efficacy in multiple animal models of SCI. We performed preliminary structure activity
relationship (SAR) studies on RO48 with three main motivations: 1) preliminary investigation of the SAR and hit-
to-lead feasibility, 2) improving the potency of RO48 in cell-based assays, and 3) generation of new composition
of matter IP to permit drug development. We were successful in demonstrating SAR and feasibility, as well as
generating new IP (International Patent Application No. PCT/US18/58411, inventors: Al-Ali et al.). Preliminary in
vitro and in vivo DMPK/Tox studies revealed that our chemistry efforts thus far have already eliminated several
liabilities of RO48. In this project, we aim to finalize the SAR studies and generate four lead candidates for animal
testing. We will then prioritize one lead to advance towards a Phase I clinical trial.
摘要
脊髓损伤(SCI)是一种具有终身后果的破坏性疾病,包括瘫痪。中央
神经系统(CNS)轴突通常不能再生,导致神经元连接的不可逆损失
以及损伤后的相关功能。SCI现在估计花费国家医疗保健系统约40.5美元
每年10亿美元(CDC)。瘫痪患者通常无法负担足够的医疗保险,
涵盖了相关的复杂的继发性或慢性疾病,这些疾病造成了巨大的经济负担,
对他们及其家人造成心理伤害。开发治疗SCI的药物将解决主要的医疗保健问题
和社会需求。
在中枢神经系统中促进轴突再生受到至少两种不同机制的挑战,
轴突生长:1)成年CNS神经元缺乏内在的再生能力,2)外在的抑制性生长。
微环境面对受损的轴突。尽管数十年的研究和数十亿美元的国家卫生研究院花费,
仍然没有批准的药物用于促进轴突再生。此外,药物在
发展可能受到以下事实的限制,即每种药物仅靶向两种生长抑制机制中的一种。
我们已经发现了第一个治疗候选药物,以小分子的形式,它可以同时
解决再生失败的两个来源。我们通过结合表型
筛选、基于靶点的分析和机器学习,以识别两种蛋白质中的激酶靶点。
机制,外在的和内在的。然后,我们确定了一个单一的小分子(RO 48),
多药理学特征与异常强劲的轴突生长促进相关。值得注意的是,RO 48显示
在SCI的多种动物模型中具有高的和可重复的功效。我们进行了初步的结构活动,
关系(SAR)研究RO 48有三个主要动机:1)SAR和命中的初步调查-
以引导可行性,2)在基于细胞的测定中提高RO 48的效力,和3)产生新的组合物
允许药物开发。我们成功地证明了SAR和可行性,以及
产生新的IP(国际专利申请号PCT/US 18/58411,发明人:Al-Ali等)。初步的
体外和体内DMPK/Tox研究表明,我们的化学努力迄今已经消除了几个
RO 48的责任在这个项目中,我们的目标是完成SAR研究,并产生四个主要候选动物,
试验.然后,我们将优先考虑一个线索,以推进I期临床试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hassan Al-Ali其他文献
Hassan Al-Ali的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hassan Al-Ali', 18)}}的其他基金
Developing a kinase inhibitor drug to treat spinal cord injury
开发治疗脊髓损伤的激酶抑制剂药物
- 批准号:
10785727 - 财政年份:2022
- 资助金额:
$ 65.03万 - 项目类别:
Developing a kinase inhibitor drug to treat spinal cord injury
开发治疗脊髓损伤的激酶抑制剂药物
- 批准号:
10710265 - 财政年份:2022
- 资助金额:
$ 65.03万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 65.03万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 65.03万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 65.03万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 65.03万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 65.03万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 65.03万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 65.03万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 65.03万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 65.03万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 65.03万 - 项目类别:
Grant-in-Aid for Scientific Research (C)